San Diego – August 24, 2016 – Cooley advised Acadia Pharmaceuticals on its follow-on offering of 6,969,696 shares of common stock for gross proceeds of $230 million.
Acadia, which trades on The NASDAQ Global Select Market as "ACAD," is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. Its portfolio includes NUPLAZID (pimavanserin), which was approved by the FDA on April 29 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis and is the only drug approved in the US for this condition.
Cooley advised ACADIA on its 2004 IPO and has since represented the company in numerous follow-on offerings.
The Cooley corporate and securities team advising Acadia included Sean Clayton, Asa Henin, Carlos Ramirez, John Ross and Kay Chandler.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.